ERBB2 and breast cancer: Given the heterogeneity of breast cancer, future studies should evaluate NAR's effects on triple‐negative (MDA‐MB‐231) and HER2‐positive (SK‐BR‐3) cell lines to determine whether its cytotoxic effects are hormone receptor‐dependent.